MedTrace Logo

Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)

NCT00280631 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2012-05-31

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of TLK199 Tablets in patients with Myelodysplastic Syndrome (MDS)

Conditions

  • Myelodysplastic Syndrome (MDS)

Interventions

DRUG

Ezatiostat Hydrochlorine

Oral Tablets in 2 Divided Doses, Dose Escalation From 200 mg Per Day to 6000 mg Per Day on Days 1-7 of each 21 Day Cycle.

Sponsors & Collaborators

  • Telik

    lead INDUSTRY

Principal Investigators

  • Gail Brown, MD · Telik

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2008-03-31
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00280631 on ClinicalTrials.gov